Issue link: https://www.e-digitaleditions.com/i/1518209
32 April 2024 Inhalation Best practices, new tests and technologies Partnering with Proveris Laboratories ensures use of industry best practices, the expertise to interpret results, and access to new technologies to accelerate orally inhaled and nasal drug product (OINDP) devel- opment. e Proveris by Design™ process, employed by Proveris Laboratories, creates the shortest path to submission for clients. By regularly integrating new tests and technologies such as spray velocity, evapora- tion fraction and human-realistic regional deposition, clients evaluate products according to the most cur- rent regulatory guidance documents and adapt devel- opment needs for product success. Learn about these techniques and see published data on the Proveris website: https://bit.ly/4bPeLyT Proveris Laboratories US: +1 508 460-8822 contactus@proveris.com www.proveris.com Advanced DPI capsule solutions Qualicaps ® , with over a century of expertise, pioneers hard capsule advancements for the pharmaceutical sector. Introducing extra dry capsules tailored for DPIs, these capsules feature minimal moisture levels and stringent microbiological protocols. Engineered for moisture-sensitive formulations, they ensure opti- mal performance in inhalation devices, facilitating the delivery of hygroscopic APIs. With Qualicaps' commitment to innovation, pharmaceuticals can now harness cutting-edge solutions for DPI formulations. Qualicaps ® Europe Spain: +34 91 663 08 00 www.qualicaps.com MDI canister coating Big changes are coming, especially related to future per- and polyfluoroalkyl substances (PFAS) bans. Biomerics can help you stay out in front of them with our new, patent pending, 100% PFAS-free metered dose inhaler (MDI) canister coating. So far, pharma- ceutical test results show equivalency to current PFAS coatings. Please reach out to us and let us know how we can support your MDI projects. Biomerics US: +1 540 246-1930 rchurchill@biomerics.com www.biomerics.com